Skip to main content
Diagnostic Medical Systems logo

Diagnostic Medical Systems — Investor Relations & Filings

Ticker · ALDMS ISIN · FR0012202497 LEI · 969500RKTIGCNNIKIN19 PA Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2026-01-06 Regulatory Filings
Country FR France
Listing PA ALDMS

About Diagnostic Medical Systems

https://www.dms.com/en/home/

Diagnostic Medical Systems (DMS) specializes in the development, design, and manufacturing of medical imaging systems. The company's core focus is on digital radiology and bone densitometry. Its product portfolio includes radiography and fluoroscopy systems, mobile x-ray units, surgical C-arms, and bone densitometers. DMS is engaged in developing next-generation imaging solutions aimed at improving patient care and personalized medicine. Key development projects include new mobile and surgical imaging equipment and an advanced range of bone densitometers for diagnosing and monitoring pathologies affecting bone mineral density.

Recent filings

Filing Released Lang Actions
HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT ON DECEMBER 31, 2025
Regulatory Filings Classification · 95% confidence The document is a report on the status of a liquidity contract, which is a specific regulatory requirement for companies listed on Euronext. It details the shares and cash held in the liquidity account as of December 31, 2025. While it is titled 'Half-Year Report', it is a specific disclosure regarding market-making activities rather than a general financial performance report (IR) or an annual report (10-K). Since it does not fit into the other specific categories like DIRS or POS, and is a standard regulatory disclosure for liquidity contracts, it falls under the RNS (Regulatory Filings) category.
2026-01-06 English
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 31 DÉCEMBRE 2025
Transaction in Own Shares Classification · 95% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract). This document details the status of a liquidity contract managed by a third party (Natixis Oddo BHF) for the company's shares. In financial reporting, disclosures regarding liquidity contracts, share buybacks, and market-making activities are categorized under 'Transaction in Own Shares' (POS) as they relate to the company's management of its own equity on the market.
2026-01-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital au 31 octobre 2025
Notice of Dividend Amount Classification · 95% confidence The document is a regulatory disclosure regarding the total number of shares and voting rights as of a specific date (October 31, 2025). This type of disclosure is a standard regulatory requirement for listed companies in France (Euronext) to inform the market about capital structure changes. Since it does not fit into specific categories like 'Share Issue' (which implies a change event) or 'Major Shareholding' (which implies a specific investor threshold), it falls under the general regulatory filing category.
2025-11-20 French
DMS GROUP RECEIVES FDA CLEARANCE FOR ITS !M1 MOBILE RADIOLOGY SYSTEM AS PART OF ITS PARTNERSHIP WITH JPI HEALTHCARE SOLUTIONS IN THE UNITED STATES
Regulatory Filings Classification · 100% confidence The document is a press release issued by DMS Group announcing FDA clearance for its !M1 mobile radiology system. It provides details on a strategic partnership, upcoming product launches, and recent revenue growth in North America. It does not constitute a formal financial report, proxy statement, or audit, but rather a corporate announcement regarding business operations and regulatory milestones. As it is a general regulatory announcement that does not fit into more specific categories like M&A or share issues, it is classified as a Regulatory Filing (RNS).
2025-11-04 English
DMS GROUP OBTIENT L'HOMOGATION DE LA FDA POUR LE MOBILE DE RADIOLOGIE !M1 DANS LE CADRE DE SON PARTENARIAT AVEC JPI HEALTHCARE SOLUTIONS AUX ÉTATS-UNIS
Regulatory Filings Classification · 100% confidence The document is a press release issued by DMS Group announcing the FDA clearance of their !M1 radiology mobile system in the US. It details a strategic partnership, product launch plans for the RSNA 2025 conference, and provides a brief update on North American revenue growth. As it is a corporate announcement regarding business operations and regulatory milestones rather than a formal financial report, it falls under the category of general regulatory announcements or corporate news.
2025-11-04 French
ACCELERATION OF GROWTH IN THE 3RD QUARTER 2025
Earnings Release Classification · 100% confidence The document is a press release titled 'ACCELERATION OF GROWTH IN THE 3 RD QUARTER 2025'. It provides a summary of consolidated revenue for the third quarter of 2025, including key highlights, business segment performance (Radiology and Bone Densitometry), geographic analysis, and future outlook. It is an initial announcement of quarterly financial results rather than a full interim report or a report publication announcement. Therefore, it fits the definition of an Earnings Release (ER). Q3 2025
2025-10-20 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.